DNA Repair Defects as a Therapeutic Target in Advanced Prostate Cancer: The Role of PARP Inhibitors

In this downloadable slideset, Johann Sebastian de Bono, MB, ChB, FRCP, MSc, PhD, reviews the available clinical data on PARP inhibitors in advanced prostate cancer and explores how these agents may affect management strategies for patients in the near future.
Johann Sebastian de Bono, MB, ChB, FRCP, MSc, PhD
Program Director
Format: Microsoft PowerPoint (.ppt)
File Size: 6.0 MB
Released: May 25, 2018

Acknowledgements

Jointly provided by Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Melissa Velasquez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

This activity is supported by an educational grant from
AstraZeneca

Related Content

Downloadable slideset reviewing the latest data on immunotherapy for patients with newly diagnosed advanced urothelial carcinoma, from Clinical Care Options (CCO)

person default Thomas Powles, MBBS, MRCP, MD Released: September 21, 2020

Downloadable slideset on the latest data on treatment for patients with progressive urothelial carcinoma and insights on new horizons for immunotherapy in urothelial carcinoma, from Clinical Care Options (CCO)

person default Alain Ravaud, MD, PhD Released: September 21, 2020

Commentary from Elizabeth R. Plimack, MD, MS on new treatment options, including erdafitinib and enfortumab vedotin, for urothelial cancer from CCO

Elizabeth R. Plimack, MD, MS Released: September 15, 2020

From ASCO 2020: analysis by Daniel P. Petrylak, MD, and Elizabeth R. Plimack, MD, MS, of key studies in renal cell carcinoma, urothelial carcinoma, and prostate cancer from CCO

Daniel P. Petrylak, MD Elizabeth R. Plimack, MD, MS Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: September 1, 2020 Expired: August 31, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue